AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $12.8333.

Several analysts recently weighed in on the company. Truist Financial lifted their price objective on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Stifel Nicolaus increased their target price on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen downgraded shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Benchmark raised shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Friday, July 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ABCL. AssuredPartners Investment Advisors LLC purchased a new stake in shares of AbCellera Biologics during the 4th quarter worth $34,000. Engineers Gate Manager LP purchased a new position in AbCellera Biologics in the fourth quarter valued at about $38,000. Allworth Financial LP grew its stake in AbCellera Biologics by 857.0% in the fourth quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock valued at $39,000 after purchasing an additional 10,096 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in AbCellera Biologics in the first quarter worth about $46,000. Finally, Magnetar Financial LLC bought a new position in AbCellera Biologics in the fourth quarter worth about $49,000. 61.42% of the stock is currently owned by hedge funds and other institutional investors.

AbCellera Biologics Stock Up 4.5%

ABCL opened at $9.76 on Wednesday. The stock’s fifty day moving average is $6.35 and its two-hundred day moving average is $4.77. The company has a market capitalization of $2.99 billion, a P/E ratio of -18.07 and a beta of 1.20. AbCellera Biologics has a 52 week low of $2.74 and a 52 week high of $10.29.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. The firm had revenue of $4.05 million for the quarter, compared to the consensus estimate of $7.85 million. Equities analysts anticipate that AbCellera Biologics will post -0.68 earnings per share for the current year.

AbCellera Biologics News Roundup

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Positive Phase 2 results validate ABCL635: The experimental non-hormonal menopause treatment met its primary efficacy endpoints and significantly reduced the frequency and severity of moderate-to-severe hot flashes. The results are being viewed as a potential efficacy benchmark and represent AbCellera’s first meaningful pipeline win, improving investor confidence in its ability to develop proprietary medicines. Reuters article
• Positive Sentiment: Analyst sharply raises valuation target: Truist Financial upgraded its price target from $12 to $30 while maintaining a “Buy” rating, signaling substantial upside potential if ABCL635 advances successfully and the company’s pipeline gains commercial traction. Benzinga article
• Positive Sentiment: Bullish trading activity increased: Investors purchased 16,666 ABCL call options, approximately 151% above typical daily volume. While not a fundamental development, the activity indicates heightened speculative interest following the clinical announcement. Options trading article
• Neutral Sentiment: Investors are reassessing the company’s growth story: Coverage broadly agrees that the menopause data are strong, but the longer-term opportunity depends on whether ABCL635 can progress through later-stage testing and whether AbCellera can produce additional successful proprietary programs.
• Negative Sentiment: Proposed $200 million offering creates dilution risk: AbCellera launched an underwritten offering of common shares and pre-funded warrants. The capital would strengthen its balance sheet and fund development, but issuing new securities may dilute existing shareholders and pressure the stock in the near term. AbCellera offering announcement
• Negative Sentiment: Valuation and platform concerns remain: Some analysts contend that the post-announcement rally leaves ABCL approximately 33% overvalued and argue that the company’s broader antibody-discovery platform narrative is losing momentum. AbCellera also remains unprofitable, increasing sensitivity to execution and financing needs.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.